Clinical Trial

Effects of Semaglutide in HIV-Associated Lipohypertrophy

Study Description

Effects of Semaglutide in HIV-Associated Lipohypertrophy

This is a randomized, double-blinded, placebo-controlled trial designed to assess the effect of the GLP-1 receptor agonist, semaglutide, on visceral and ectopic fat, insulin resistance, inflammation markers, and the downstream effect of cardiovascular risk in people with HIV. A similarly-designed study will enroll overweight/obese participants without HIV who will match the participants with HIV by gender, age, and BMI, and will run in parallel to the HIV study. The primary endpoints will be visceral and ectopic fat changes over the study period. The secondary endpoints will include changes in markers of inflammation, immune activation, gut integrity, and cardiovascular disease risk assessment.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Semaglutide Injectable Product

semaglutide subcutaneous injection

Drug - Placebo

placebo injection

Additional Information

Official Study Title

Effects of GLP-l Receptor Agonists on Cardiometabolic Alterations in HIV-associated Lipohypertrophy

Clinical Trial ID

NCT04019197

ParticipAid ID

en5AWd